Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus PT from Brokerages
01:31am, Friday, 27'th Mar 2026
Shares of Lucid Diagnostics Inc. (NASDAQ: LUCD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, Ma
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
05:15pm, Thursday, 26'th Mar 2026
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates
10:10am, Thursday, 26'th Mar 2026
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.19 per share a year ago.
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
08:00am, Thursday, 26'th Mar 2026
Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with p
PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026
09:01am, Monday, 16'th Mar 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
09:01am, Thursday, 12'th Mar 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical d
Lucid Diagnostics (NASDAQ:LUCD) & Alpha Tau Medical (NASDAQ:DRTS) Financial Survey
04:44am, Friday, 20'th Feb 2026
Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) and Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast t
Inogen (INGN) Soars 6.6%: Is Further Upside Left in the Stock?
08:11am, Thursday, 12'th Feb 2026
Inogen (INGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
08:01am, Wednesday, 04'th Feb 2026
Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare loc
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
08:00am, Wednesday, 21'st Jan 2026
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
Contrasting Lucid Diagnostics (NASDAQ:LUCD) & Waters (NYSE:WAT)
02:04am, Saturday, 10'th Jan 2026
Waters (NYSE: WAT - Get Free Report) and Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the
Reviewing Intuitive Surgical (NASDAQ:ISRG) and Lucid Diagnostics (NASDAQ:LUCD)
01:54am, Friday, 02'nd Jan 2026
Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) and Intuitive Surgical (NASDAQ: ISRG - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two co
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
08:01am, Tuesday, 09'th Dec 2025
Report includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection Device Real-world data confirm excellen
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
08:15am, Thursday, 20'th Nov 2025
Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Lucid Dia
Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Recommendation of “Moderate Buy” by Brokerages
03:11am, Wednesday, 19'th Nov 2025
Lucid Diagnostics Inc. (NASDAQ: LUCD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the stock, Marketbeat.co
